All News

Rosetta Genomics, which has a test to identify tissues of origin for metastatic cancers with an unknown primary, just won back the rights to market its own test in the US. But it's expected to post a loss this year. If it can find missing cancers, why isn't Rosetta rolling in cash?

Dear Colleague: Targeted therapies and personalized medicine have become two major buzzwords in cancer care. But as breast cancer specialists, we have incorporated both into our practice for some time. For instance, tamoxifen is a targeted therapy, although we didn’t necessarily call it by that name. When it comes to personalized medicine, one of our goals has been to find better prognostic and predictive factors: Can we identify which patients will benefit from a specific therapy? Can we pinpoint those patients who can safely avoid chemotherapy? The 2010 San Antonio Breast Cancer Symposium (SABCS) offers all breast cancer specialists the chance to explore the wealth of data that we have amassed over the years. Join Oncology NEWS International for onsite reports from SABCS 2010 as we bring you a bird’s eye view of the research, trials, scientific advances, and controversies that are changing the way breast cancer is managed and treated. Check back here daily during the meeting and watch your inbox for our exciting reports from the SABCS 2010.

ONCOLOGYNURSE EDITIONApril 2011Volume 25 • Number 4Subscribe  |  Publication Services  |   ArchivesONCOLOGY's Nurse Edition publishes articles related to practical management issues in the care of patients with neoplastic disease. Through the Nurse Edition, ONCOLOGY aims to provide readers with useful insights into all aspects of patient management, with an emphasis on information and tools that can be applied to daily practice and patient education.

Please take a moment to help us serve you better and receive a $10 Amazon gift card just for participating.  CancerNetwork.com would like to know about the challenges you face in your profession and how you stay up-to-date on the latest information affecting patient care.  This survey should only take a few moments of your time.  In order to participate in the survey and receive your $10 Amazon gift card, you must first be a registered member of CancerNetwork.com.  After completing the registration, you will be directed to the survey link.

Offer Terms: Offer available only to licensed physicians who register as members of CancerNetwork.com prior to November 30, 2010, subject to UBM Medica's verification of member's licensure status. Registrants must be (i) legal residents of the fifty United States (and the District of Columbia), (ii) at least 18 years of age, and (iii) licensed physicians, as of the date of their registration. Employees of UBM Medica, its parent company, affiliates and subsidiaries, and their agents, subcontractors, suppliers, as well as the immediate family (spouse, parents, siblings, and children) and household members of each such employee are not eligible to receive incentive. Limit 1 gift card per person. Offer is not retroactive to previously registered members. The gift card code will be e-mailed to you within 7 - 10 business days of November 30, 2010 at the e-mail address on file with UBM Medica (in user’s member profile). E-mail address on file must be a valid, working e-mail address in order to receive incentive.  

A $3 billion cancer research program created by Texas voters in 2007 has set its primary goal as creating a new cancer trials network that will address the shortcomings of existing systems for clinical cancer research.

What should we do to fix this situation?

Vitamin B12 is part of the vitamin B complex and is essential for maintaining nerve function, fatty acid metabolism, and DNA and amino acid synthesis. By lowering homocysteine levels, it may also protect against cardiovascular disease. Vitamin B12 can be obtained through diet (including eggs, dairy products, poultry, meat, and fortified cereals) and in supplement form. Deficiency of B12 can lead to a wide variety of hematologic, neurologic, and psychiatric disorders and may increase the risk of cardiovascular diseases. Clinical evidence to support the role of vitamin B12 in decreasing cancer risk is mixed. Further research is needed.

Despite the fact that elderly patients comprise over 50% of the non-small cell lung cancer (NSCLC) population, our knowledge regarding the efficacy and safety of chemotherapy in this group is suboptimal. The “elderly” (defined as individuals ≥70 years of age) experience physiologically normal aging of their bone marrow and kidneys, which inherently increases toxicity to therapy. Standard practice has often been to discourage the use of combination chemotherapy in these patients; however, general consensus guidelines emphasize that performance status should primarily guide the choice of treatment. Elderly patients with advanced NSCLC treated with platinum doublet therapy demonstrate similar efficacy (but increased toxicity) to their younger counterparts. Patients with metastatic disease in which a targeted and/or biological agent(s) was added to chemotherapy experienced benefits similar to those treated with standard platinum doublets, but with increased morbidity and mortality. In the future, effective testing of molecular targeted therapies will have to include elderly patients among research cohorts or risk excluding a large population of eligible patients. Overall, elderly patients with advanced NSCLC, while experiencing greater toxicity, demonstrate the same response rates and survival benefits as their younger peers.

Calendar age and biological age do not always correspond. Pablo Picasso, source of the quote that begins the title of this commentary, lived a notoriously robust and active life through his later decades, dying in his nineties in the midst of a dinner party. In the oncology community, with the advent of targeted therapeutics and better supportive care, the disparity between the two is likely to be increasingly relevant to both research and practice. In this issue of ONCOLOGY, Chiappori et al review data supporting the idea that even in the context of standard cytotoxic chemotherapy, elderly patients with advanced NSCLC experience similar response rates and similar survival benefits to those seen in younger patients. They note that biases excluding elderly patients from clinical trials result in gaps in our knowledge of how to best treat older patients.

The review by Dr. Chiappori and colleagues in this issue of ONCOLOGY addresses an important challenge relating to the optimal management of elderly patients with lung cancer. The authors provide an excellent overview of the data in patients with various stages of non-small cell lung cancer (NSCLC). They also highlight the limitations of the existing data in the management of elderly NSCLC patients.

Nothing gets biopharma policy watchers more worked up than the possibility that the Centers for Medicare & Medicaid Services (CMS) will second-guess FDA approval decisions. In reality, though, CMS often has no choice but to apply its own interpretation to issues that also fall under the FDA’s jurisdiction-and implementation of the health care reform is bringing more of those cases to the fore.

Kaiser Health asked the question, see P&P contributor’s answer

The Fred Hutchinson Cancer Research Center has signed a formal agreement with China's version of the CDC. One goal is to carry out research on large datasets, with the aim of finding new cancer biomarkers.

This is important, mark your calender! Final Rules webinar on Thursday, December 2, 2010

McKesson plans to spend more than $2 billion to purchase the largest community-based cancer treatment and research network in America.

Exit polls show that health-care took a back seat to the economy. But the GOP is bent on reforming the Reform. Check out the early analysis from major news outlets.

Up-to-date drug and vendor news in hematology.

ASTRO appoints a new board of directors and bestows several awards at its 2010 meeting. Learn more about the latest appointments and accolades in cancer care.

Dear Colleague: In recent years, experts in the field of hematologic malignancies have seen a panoply of drugs gain a place in our treatment armamentarium. Some of the breakthroughs include the approval of histone deacetylase (HDAC) inhibitors in chronic lymphocytic leukemia (CLL) and peripheral lymphoma; the application of novel alkylating agents, such as bendamustine (Treanda), in CLL and various lymphomas; and the incorporation of dasatinib (Sprycel) for treating chronic myeloid leukemia patients who prove resistant to imatinib (Gleevec). We now find ourselves focusing on how to design the most effective strategies, including drug sequencing, to maximize benefit for our patients. The 2010 American Society of Hematology meeting (ASH) offers the chance to delve deeper into the best ways to maximize treatment for our patients. Join Oncology NEWS International for onsite reports from ASH 2010 as we bring you a bird’s eye view of the research, trials, scientific advances, and controversies that are changing the way hematologic malignancies are managed and treated. Check back here daily during the meeting and watch your inbox for our exciting reports from the ASH 2010 meeting.

Check out this summary of healthcare policy coverage from the major news organizations

Surveys have shown that the mean days in accounts receivable for US oncology practices averages about 36 days. With today’s slim margins, your AC department needs to do a better job.

New guidelines advise caution advised when prescribing epoetin and darbepoetin

Rhetoric aside, initiatives such as comparative effectiveness and ACOs are designed to cut the costs of healthcare. Is there a way to effectively cut the cost of cancer care and maintain quality?

Noni is an evergreen plant prevalent in Southeast Asia, Australia, and the Polynesian islands. It is used in traditional medicine for wound healing, infections, skin conditions, diarrhea, and as a tonic. Noni products have gained worldwide popularity over the past 2 decades and are aggressively marketed for immunostimulation and for treatment of chronic fatigue syndrome and cancer.Preliminary data from in vitro and animal studies suggest immunomodulatory, antioxidant, and antitumor properties. However, hepatotoxicity and hyperkalemia have also been reported with noni use.